Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation

S. Sumi, R. D. Beauchamp, Courtney Townsend, P. M. Pour, J. Ishizuka, J. C. Thompson

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Lovastatin, an inhibitor of the rate-limiting enzyme of cholesterol synthesis, inhibits growth of pancreatic cancer cells. A possible mechanism of this inhibition is that lovastatin inhibits the activity of RAS protein by depleting farnesyl (an intermediate of cholesterol synthesis). The K-ras gene is frequently mutated in pancreatic cancers and RAS protein requires farnesyl to be bound to the cell membrane and thereby activated. To investigate whether lovastatin inhibition of cell growth depends upon the presence of ras mutation, codons 12/13 and 61 of ras genes were examined by the dideoxynucleotide chain-terminating method in five pancreatic cell lines (human CAPAN2, CAV, MIA Paca2, PANC1, and hamster H2T) on which lovastatin exerted a growth-inhibitory effect. These codons play a major role in tumorigenic mutation of ras genes. Lovastatin inhibited cell growth by 99% (MIA), 97% (H2T), 78% (CAV), 41% (CAPAN2), and 23% (PANC1), respectively, when cells were treated with 2.5 μg/ml lovastatin for 6 days. Activating point mutations were found in codon 12 of the K-ras gene (wild type:GGT) in MIA (GTT), H2T (GAT), CAPAN2 (TGT), and PANC1 (GAT) but not in CAV. In addition, the CAV cell line did not have a mutation in either H- or N-ras genes. Lovastatin inhibited the growth of CAV cells even though this cell line did not have ras mutation, suggesting that lovastatin inhibition of pancreatic cancer cell growth is not directly dependent on the presence of ras mutation.

Original languageEnglish (US)
Pages (from-to)657-661
Number of pages5
JournalPancreas
Volume9
Issue number5
StatePublished - 1994

Fingerprint

Lovastatin
Pancreatic Neoplasms
ras Genes
Mutation
Growth
Codon
Cell Line
Dideoxynucleotides
Cholesterol
Point Mutation
Cricetinae
Proteins
Cell Membrane
Enzymes

Keywords

  • Lovastatin
  • Pancreatic cancer
  • ras mutation

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Sumi, S., Beauchamp, R. D., Townsend, C., Pour, P. M., Ishizuka, J., & Thompson, J. C. (1994). Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas, 9(5), 657-661.

Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. / Sumi, S.; Beauchamp, R. D.; Townsend, Courtney; Pour, P. M.; Ishizuka, J.; Thompson, J. C.

In: Pancreas, Vol. 9, No. 5, 1994, p. 657-661.

Research output: Contribution to journalArticle

Sumi, S, Beauchamp, RD, Townsend, C, Pour, PM, Ishizuka, J & Thompson, JC 1994, 'Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation', Pancreas, vol. 9, no. 5, pp. 657-661.
Sumi S, Beauchamp RD, Townsend C, Pour PM, Ishizuka J, Thompson JC. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas. 1994;9(5):657-661.
Sumi, S. ; Beauchamp, R. D. ; Townsend, Courtney ; Pour, P. M. ; Ishizuka, J. ; Thompson, J. C. / Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. In: Pancreas. 1994 ; Vol. 9, No. 5. pp. 657-661.
@article{2f9ec35fe2474f0789483da8d26734c1,
title = "Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation",
abstract = "Lovastatin, an inhibitor of the rate-limiting enzyme of cholesterol synthesis, inhibits growth of pancreatic cancer cells. A possible mechanism of this inhibition is that lovastatin inhibits the activity of RAS protein by depleting farnesyl (an intermediate of cholesterol synthesis). The K-ras gene is frequently mutated in pancreatic cancers and RAS protein requires farnesyl to be bound to the cell membrane and thereby activated. To investigate whether lovastatin inhibition of cell growth depends upon the presence of ras mutation, codons 12/13 and 61 of ras genes were examined by the dideoxynucleotide chain-terminating method in five pancreatic cell lines (human CAPAN2, CAV, MIA Paca2, PANC1, and hamster H2T) on which lovastatin exerted a growth-inhibitory effect. These codons play a major role in tumorigenic mutation of ras genes. Lovastatin inhibited cell growth by 99{\%} (MIA), 97{\%} (H2T), 78{\%} (CAV), 41{\%} (CAPAN2), and 23{\%} (PANC1), respectively, when cells were treated with 2.5 μg/ml lovastatin for 6 days. Activating point mutations were found in codon 12 of the K-ras gene (wild type:GGT) in MIA (GTT), H2T (GAT), CAPAN2 (TGT), and PANC1 (GAT) but not in CAV. In addition, the CAV cell line did not have a mutation in either H- or N-ras genes. Lovastatin inhibited the growth of CAV cells even though this cell line did not have ras mutation, suggesting that lovastatin inhibition of pancreatic cancer cell growth is not directly dependent on the presence of ras mutation.",
keywords = "Lovastatin, Pancreatic cancer, ras mutation",
author = "S. Sumi and Beauchamp, {R. D.} and Courtney Townsend and Pour, {P. M.} and J. Ishizuka and Thompson, {J. C.}",
year = "1994",
language = "English (US)",
volume = "9",
pages = "657--661",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation

AU - Sumi, S.

AU - Beauchamp, R. D.

AU - Townsend, Courtney

AU - Pour, P. M.

AU - Ishizuka, J.

AU - Thompson, J. C.

PY - 1994

Y1 - 1994

N2 - Lovastatin, an inhibitor of the rate-limiting enzyme of cholesterol synthesis, inhibits growth of pancreatic cancer cells. A possible mechanism of this inhibition is that lovastatin inhibits the activity of RAS protein by depleting farnesyl (an intermediate of cholesterol synthesis). The K-ras gene is frequently mutated in pancreatic cancers and RAS protein requires farnesyl to be bound to the cell membrane and thereby activated. To investigate whether lovastatin inhibition of cell growth depends upon the presence of ras mutation, codons 12/13 and 61 of ras genes were examined by the dideoxynucleotide chain-terminating method in five pancreatic cell lines (human CAPAN2, CAV, MIA Paca2, PANC1, and hamster H2T) on which lovastatin exerted a growth-inhibitory effect. These codons play a major role in tumorigenic mutation of ras genes. Lovastatin inhibited cell growth by 99% (MIA), 97% (H2T), 78% (CAV), 41% (CAPAN2), and 23% (PANC1), respectively, when cells were treated with 2.5 μg/ml lovastatin for 6 days. Activating point mutations were found in codon 12 of the K-ras gene (wild type:GGT) in MIA (GTT), H2T (GAT), CAPAN2 (TGT), and PANC1 (GAT) but not in CAV. In addition, the CAV cell line did not have a mutation in either H- or N-ras genes. Lovastatin inhibited the growth of CAV cells even though this cell line did not have ras mutation, suggesting that lovastatin inhibition of pancreatic cancer cell growth is not directly dependent on the presence of ras mutation.

AB - Lovastatin, an inhibitor of the rate-limiting enzyme of cholesterol synthesis, inhibits growth of pancreatic cancer cells. A possible mechanism of this inhibition is that lovastatin inhibits the activity of RAS protein by depleting farnesyl (an intermediate of cholesterol synthesis). The K-ras gene is frequently mutated in pancreatic cancers and RAS protein requires farnesyl to be bound to the cell membrane and thereby activated. To investigate whether lovastatin inhibition of cell growth depends upon the presence of ras mutation, codons 12/13 and 61 of ras genes were examined by the dideoxynucleotide chain-terminating method in five pancreatic cell lines (human CAPAN2, CAV, MIA Paca2, PANC1, and hamster H2T) on which lovastatin exerted a growth-inhibitory effect. These codons play a major role in tumorigenic mutation of ras genes. Lovastatin inhibited cell growth by 99% (MIA), 97% (H2T), 78% (CAV), 41% (CAPAN2), and 23% (PANC1), respectively, when cells were treated with 2.5 μg/ml lovastatin for 6 days. Activating point mutations were found in codon 12 of the K-ras gene (wild type:GGT) in MIA (GTT), H2T (GAT), CAPAN2 (TGT), and PANC1 (GAT) but not in CAV. In addition, the CAV cell line did not have a mutation in either H- or N-ras genes. Lovastatin inhibited the growth of CAV cells even though this cell line did not have ras mutation, suggesting that lovastatin inhibition of pancreatic cancer cell growth is not directly dependent on the presence of ras mutation.

KW - Lovastatin

KW - Pancreatic cancer

KW - ras mutation

UR - http://www.scopus.com/inward/record.url?scp=0027934414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027934414&partnerID=8YFLogxK

M3 - Article

C2 - 7809022

AN - SCOPUS:0027934414

VL - 9

SP - 657

EP - 661

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -